Prof. S.-E. Al-Batran
Prof. A. Vogel
Prof. S.-E. Al-Batran
welcome to the website of the PLATON network.
PLATON intends to improve the individualized, targeted therapy for patients in different cancer entities by bringing together molecular profiles, clinical data, and study data.
As a key feature, PLATON provide participating physicians with the opportunity to conduct Next Generation Sequencing for their patients and enter the molecular profiles, the key clinical data and the available trials into a specialized data base.
One other key feature of PLATON is an interactive, internet-based platform, in which participating physicians exchange these information to increase the likelihood of treating the patients with an individualized therapy.
In addition, PLATON investigates the predictive and prognostic impact of the detected molecular alterations. In a pilot phase, 200 patients will be enrolled.
We are looking forward to welcoming you in the PLATON network.
“Precision oncology has gained increased recognition in recent years, but significant challenges for the routine implementation of personalized concepts into daily clinical practice prevail.”
PLATON’s Study Design
PLATON is a dynamic platform that increases the awareness of molecular testing, enhances the visibility of clinical trials, and fosters professional exchange. PLATON was conceived to help cancer patients suffering from different types of GI cancers, receive the best available, scientifically founded, biomarker-based care, tailored to their individual needs. The framework is designed as:
- multicentre, prospective, observational cohort study with biobanking
- platform-design with associated sub-studies
- open no. of participants (pilot-phase 200 patients)
- open no. of study-sites (pilot-phase 40 sites)
“Within PLATON’s framework the infrastructure is designed to increase the likelihood of treating the patients with a personalized therapy in clinical studies.”
PLATON’s Study Objectives
- # To assess the frequency of targetable mutations (incl. TMB and MSI status) per disease groupy
- # To analyze the number of patients receiving therapies based on their genomic profile
- # To assess the frequency of targetable mutations and associated therapy decisions
- # To evaluate the differences in targetable alterations in FFPE specimen vs. cfDNA (pilot-phase)
- # To analyze overall survival (OS) acc. to molecular profile
- # To establish a data and sample collection for future research
- # To validate the feasibility of the PLATON Network framework:
- – to search on cases, cancer types, mutations and clinical studies
- – to browse possible cincial trials and therapy options matching the individual molecular profiles
- – to discussion therapy options with other medical professionals
PLATON's Project Management Team
Dr. rer. physiol. Claudia Pauligk
Dipl.-Biol. Bianca Zäpf
M. Sc. Neurobiology Felicia Michael
For more information on participation in the PLATON Network please contact: firstname.lastname@example.org
Institut für Klinische Krebsforschung IKF GmbH
at Krankenhaus Nordwest
Steinbacher Hohl 2-26
60488 Frankfurt am Main